PCNA and lung cancer: The involvement of PPARβ/δ in lung cancer was first reported in an in vitro study showing that the agonist L-165041 induces growth inhibition of A549 cells, as evidenced by decreased expression of the proliferation marker proliferating cell nuclear antigen (PCNA) [37].